GlassScriptPhysician profile
Maqbool Ahmed
NPI 1548300916
$10,327.02
in general payments reported to CMS, 2019-2025
48 companies · $3,144 in 2025
The $3,144 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $584 · 2021: $2,208 · 2022: $566 · 2023: $1,865 · 2024: $1,543 · 2025: $3,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,353 · Consulting Fee: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,352.80 |
| Consulting Fee | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,420.75 | 2021-2025 | Opdualag |
| Lilly USA, LLC | $688.05 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Sk Life Science, INC. | $637.22 | 2020-2025 | |
| Biogen, INC. | $632.19 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Eisai INC. | $554.14 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $416.06 | 2019-2022 | |
| Abbvie INC. | $399.91 | 2024-2025 | |
| Ceribell, INC. | $371.76 | 2025 | Pocket Eeg Device |
| Sumitomo Pharma America, INC. | $343.08 | 2023-2024 | Aptiom |
| Alexion Pharmaceuticals, INC. | $250.06 | 2019-2025 | Ultomiris |
| Lundbeck LLC | $245.95 | 2020-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $243.51 | 2021-2024 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $240.96 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $229.83 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Emd Serono, INC. | $224.71 | 2023-2025 | Mavenclad |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $188.38 | 2019-2025 | Crexont, Ongentys 50mg Capsules 30, Rytary |
| Amgen INC. | $170.62 | 2019-2025 | Uplizna |
| Ucb, INC. | $164.30 | 2024-2025 | Briviact, Nayzilam |
| Tg Therapeutics, INC. | $158.55 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $152.56 | 2020-2025 | Austedo Xr, Austedo Xr |
| Neurelis, INC. | $136.85 | 2023-2025 | Valtoco |
| Axsome Therapeutics, INC. | $131.35 | 2025 | Symbravo, Sunosi |
| Pfizer INC. | $121.41 | 2024-2025 | |
| Genentech USA, INC. | $95.02 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Ani Pharmaceuticals, INC. | $91.38 | 2024-2025 | Purified Cortrophin Gel |
| Supernus Pharmaceuticals, INC. | $91.14 | 2019-2022 | |
| Mdd US Operations, LLC | $86.77 | 2021 | |
| Acadia Pharmaceuticals INC | $83.19 | 2019-2025 | Nuplazid |
| Astrazeneca Pharmaceuticals LP | $81.41 | 2024-2025 | Wainua, Andexxa |
| Csl Behring | $71.32 | 2019-2025 | Hizentra |
| Janssen Pharmaceuticals, INC | $70.96 | 2020-2022 | |
| Argenx US, INC. | $61.56 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Jazz Pharmaceuticals INC. | $54.94 | 2024 | |
| Harmony Biosciences LLC | $53.02 | 2025 | |
| Livanova USA, INC. | $47.76 | 2021-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Merz Pharmaceuticals, LLC | $40.80 | 2024-2025 | Xeomin |
| C2n Diagnostics, LLC | $35.19 | 2025 | Precivityad2 |
| Grifols USA, LLC | $30.23 | 2024 | Gamunex-C |
| Ge Healthcare | $28.39 | 2021-2025 | |
| Genzyme Corporation | $23.85 | 2025 | |
| Cycle Pharmaceuticals INC | $23.13 | 2024 | Tiopronin |
| Janssen Biotech, INC. | $22.44 | 2025 | |
| Vanda Pharmaceuticals INC. | $20.57 | 2024 | Ponvory |
| Life Molecular Imaging LTD | $19.30 | 2025 | Neuraceq |
| Catalyst Pharmaceuticals, INC. | $19.05 | 2025 | |
| Portola Pharmaceuticals, LLC | $18.67 | 2019 | |
| Tanabe Pharma America, INC. | $18.24 | 2020 | |
| Averitas Pharma INC. | $16.49 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maqbool Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.